<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03011372</url>
  </required_header>
  <id_info>
    <org_study_id>INCB 54828-203</org_study_id>
    <nct_id>NCT03011372</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement</brief_title>
  <official_title>A Phase 2, Open-Label, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Incyte Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Incyte Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of INCB054828 in subjects
      with myeloid/lymphoid neoplasms with fibroblast growth factor receptor (FGFR) 1
      rearrangement.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 26, 2016</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">October 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall clinical benefit rate based on response criteria for myeloid/lymphoid neoplasms with FGFR1 rearrangement</measure>
    <time_frame>Assessed at protocol-defined timepoints through end of study, up to approximately 24 months.</time_frame>
    <description>Clinical benefit rate defined as the proportion of subjects who achieved a complete response (CR), partial response (PR), complete hematologic response (CHR), cytogenetic response, marrow response, or clinical benefit.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of response/benefit</measure>
    <time_frame>Assessed at protocol-defined timepoints through end of study, up to approximately 24 months.</time_frame>
    <description>Defined as the time from the date when the subject first achieves response/benefit until the date of the first documented disease progression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>From the date of first study drug dose until the date of disease progression or until death due to any cause, whichever is earlier, assessed up to approximately 24 months.</time_frame>
    <description>PFS is defined as the time from the first date of taking study drug until the date of disease progression, as measured by response criteria for myeloid/lymphoid neoplasms with FGFR1 rearrangement, or until death due to any cause, whichever is earlier.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>From date of first study drug dose until death due to any cause, assessed up to approximately 24 months.</time_frame>
    <description>Overall survival is defined as the time from the first day of taking study drug until death due to any cause. Subjects without death observed at the time of the analysis will be censored at last date known to be alive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability as assessed by frequency, duration, and severity of adverse events</measure>
    <time_frame>From baseline through 30-35 days after end of treatment, up to 7 months per individual subject</time_frame>
    <description>A treatment-emergent AE was defined as an event occurring after exposure to at least 1 dose of study drug. A treatment-related AE was defined as an event with a definite, probable, or possible causality to study medication. A serious AE is an event resulting in death, hospitalization, persistent or significant disability/incapacity, or is life threatening, a congenital anomaly/birth defect or requires medical or surgical intervention to prevent 1 of the outcomes above. The intensity of an AE was graded according to the National Cancer Institute common terminology criteria for adverse events (NCI-CTCAE) version 4.03: Grade 1 (Mild); Grade 2 (Moderate); Grade 3 (Severe); Grade 4 (life-threatening).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">46</enrollment>
  <condition>MPN (Myeloproliferative Neoplasms)</condition>
  <arm_group>
    <arm_group_label>INCB054828</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INCB054828</intervention_name>
    <description>INCB054828 at the protocol-defined once-daily dose.</description>
    <arm_group_label>INCB054828</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Documented lymphoid or myeloid neoplasm with 8p11 rearrangement known to lead to FGFR1
             activation, based on standard diagnostic cytogenetic evaluation performed locally,
             before signing informed consent for this study.

          -  Subjects must be relapsed/refractory. Prior stem cell transplantation is allowed.

          -  Life expectancy â‰¥ 12 weeks.

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2.

        Exclusion Criteria:

          -  Prior receipt of a selective FGFR inhibitor.

          -  History and/or current evidence of ectopic mineralization/calcification, including but
             not limited to soft tissue, kidneys, intestine, myocardia, or lung, except calcified
             lymph nodes and asymptomatic arterial or cartilage/tendon calcifications.

          -  Current evidence of corneal disorder/keratopathy, including but not limited to
             bullous/band keratopathy, corneal abrasion, inflammation/ulceration, and
             keratoconjunctivitis, as confirmed by ophthalmologic examination.

          -  Use of any potent cytochrome P450 3A4 inhibitors or inducers within 14 days or 5
             half-lives (whichever is shorter) before the first dose of study drug.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ekaterine Asatiani, MD</last_name>
    <role>Study Director</role>
    <affiliation>Incyte Corporation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Incyte Corporation Call Center</last_name>
    <phone>1.855.463.3463</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Incyte Corporation Call Center (ex-US)</last_name>
    <phone>+800 00027423</phone>
    <email>globalmedinfo@incyte.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator William Bals</last_name>
      <phone>480-342-6034</phone>
      <email>bals.william@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Jeanne Palmer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford Cancer Institute</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator Justin Abuel</last_name>
      <phone>650-723-1367</phone>
      <email>jabuel@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Jason Gotlib</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Winship Cancer Institute of Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator Shannon Gleason</last_name>
      <phone>404-778-4334</phone>
      <email>shannon.gleason@emory.edu</email>
    </contact>
    <investigator>
      <last_name>Elliott Winton</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Franciscan Health Cancer Center - Indiana Blood and Marrow Transplantation</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46237</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator Melanie Coleman</last_name>
      <phone>317-528-7298</phone>
      <email>melanie.coleman@franciscanalliance.org</email>
    </contact>
    <investigator>
      <last_name>Luke Akard</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University Division of Hematology</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator Karyn Gordon</last_name>
      <phone>314-362-0156</phone>
      <email>kdgordon@wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Stephen Oh</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical College</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator Tiffany Cortes</last_name>
      <phone>212-746-1534</phone>
      <email>tic2013@med.cornell.edu</email>
    </contact>
    <investigator>
      <last_name>Ellen Ritchie</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson Leukemia Dept</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator Kurt Schroeder</last_name>
      <phone>713-563-2622</phone>
      <email>kdschroe@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Srdan Verstovsek</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Huntsman Cancer Institute</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator Blake Cope</last_name>
      <phone>801-587-9178</phone>
      <email>blake.cope@hci.utah.edu</email>
    </contact>
    <investigator>
      <last_name>Michael Deininger</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Krankenhaus der Barmherzigen Schwestern Linz Betriebsgesellschaft m.b.H.</name>
      <address>
        <city>Linz</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator Angela Plasser</last_name>
      <phone>+43 732 7677 4319</phone>
      <email>Angela.plasser@ordensklinikum.at</email>
    </contact>
    <investigator>
      <last_name>Andreas Petzer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hanusch-Krankenhaus</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator Astrid Grassler</last_name>
      <phone>+43 1 91021 85421</phone>
      <email>astrid.grassler@wgkk.at</email>
    </contact>
    <investigator>
      <last_name>Thamer Sliwa</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medizinische UniversitÃ¤t Wien</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator Renate Schoder</last_name>
      <phone>+43 1 40400 812227</phone>
      <email>renate.schoder@meduniwien.ac.at</email>
    </contact>
    <investigator>
      <last_name>Heinz Gisslinger</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Nice, HÃ´pital l'Archet</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator Irit Touitou</last_name>
      <phone>+33 4 92 03 90 87</phone>
      <email>touitou.i@chu-nice.fr</email>
    </contact>
    <investigator>
      <last_name>Laurence Legros</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HÃ´pital Saint-Louis</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator Souhil Allaoua</last_name>
      <phone>+33 1 42 38 54 42</phone>
      <email>souhil.allaoua@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-Jacques Kiladjian</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Universitaire du Cancer de Toulouse - OncopÃ´le</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator Amandine Virlojeux</last_name>
      <phone>+33 5 31 15 63 30</phone>
      <email>virlojeux.amandine@iuct-oncopole.fr</email>
    </contact>
    <investigator>
      <last_name>Francoise Huguet</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UniversitÃ¤tsklinikum Aachen, Klinik fÃ¼r HÃ¤matologie, Onkologie, HÃ¤mostaseologie und Stammzelltransplantation</name>
      <address>
        <city>Aachen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator Sabrina Holst</last_name>
      <phone>+49 2 418 037 141</phone>
      <email>sholst@ukaachen.de</email>
    </contact>
    <investigator>
      <last_name>Steffen Koschmieder</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UniversitÃ¤tsklinikum Halle (Saale) Klinik fÃ¼r Innere Medizin IV Onkologie/HÃ¤matologie/HÃ¤mostaseologie Landeszentrum fÃ¼r Zell- und Gentherapie</name>
      <address>
        <city>Halle (Saale)</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator Karolin Hubert</last_name>
      <phone>+49 3 455 577260</phone>
      <email>karolin.hubert@uk-halle.de</email>
    </contact>
    <investigator>
      <last_name>Haifa Kathrin Al-Ali</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UniversitÃ¤tsklinikum Jena Klinik und Poliklinik fÃ¼r Innere Medizin II</name>
      <address>
        <city>Jena</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator Marina Liebing</last_name>
      <phone>+49 3641 9396675</phone>
      <email>marina.liebing@med.uni-jena.de</email>
    </contact>
    <investigator>
      <last_name>Andreas Hochhaus</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UniversitÃ¤tsklinikum Leipzig</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator Thomas Schliwa</last_name>
      <phone>+49 3 419 713 131</phone>
      <email>thomas.schliwa@medizin.uni-leipzig.de</email>
    </contact>
    <investigator>
      <last_name>Dietger Niederwieser</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medizinischen FakultÃ¤t Mannheim der UniversitÃ¤t Heidelberg</name>
      <address>
        <city>Mannheim</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator Cornelia Willersinn</last_name>
      <phone>+49 6 213 834 169</phone>
      <email>cornelia.willersinn@umm.de</email>
    </contact>
    <investigator>
      <last_name>Andreas Reiter</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johannes Wesling Klinikum Minden, UniversitÃ¤tsklinik fÃ¼r HÃ¤matologie, Onkologie, GerinnungsstÃ¶rungen und Palliativmedizin (UniversitÃ¤tszentrum Innere Medizin)</name>
      <address>
        <city>Minden</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator Vera Kolatzki</last_name>
      <phone>+49 571 7901184</phone>
      <email>vera.kolatzki@muehlenkreiskliniken.de</email>
    </contact>
    <investigator>
      <last_name>Martin Griesshammer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A. O. PAPA GIOVANNI XXIII (ex Ospedali Riuniti)</name>
      <address>
        <city>Bergamo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator Gaia Bonacina</last_name>
      <phone>+39 352 674657</phone>
      <email>ematosc@asst-pg23.it</email>
    </contact>
    <investigator>
      <last_name>Alessandro Rambaldi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Careggi</name>
      <address>
        <city>Florence</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator Chiara Paoli</last_name>
      <phone>+39 55 7947688</phone>
      <email>chiara.paoli@unifi.it</email>
    </contact>
    <investigator>
      <last_name>Alessandro Vannucchi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator Lucia Brines</last_name>
      <phone>+34 96 197 35 83</phone>
      <email>luciabrinsi@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Juan Carlos Hernandez Boluda</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inselspital Bern</name>
      <address>
        <city>Bern</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator Renata Bunter</last_name>
      <phone>+41 31 632 34 57</phone>
      <email>renata.buenter@ctu.unibe.ch</email>
    </contact>
    <investigator>
      <last_name>Gabriela Baerlocher</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinik fÃ¼r HÃ¤matologie - University of Zurich</name>
      <address>
        <city>Zurich</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator Julia Stickelberger</last_name>
      <phone>+41 442559565</phone>
      <email>julia.stickelberger@usz.ch</email>
    </contact>
    <investigator>
      <last_name>Stefan Balabanov</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Guy's and St Thomas' NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator Trisha Enes</last_name>
      <phone>+44 2 07 18847188</phone>
      <email>trisha.enes@gstt.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Claire Harrison</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oxford University Hospitals NHS Trust - Churchill Hospital</name>
      <address>
        <city>Oxford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator Sally Springett</last_name>
      <phone>+44 1 865 572 023</phone>
      <email>sally.springett@ouh.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Adam Mead</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 4, 2017</study_first_submitted>
  <study_first_submitted_qc>January 4, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 5, 2017</study_first_posted>
  <last_update_submitted>February 20, 2018</last_update_submitted>
  <last_update_submitted_qc>February 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Myeloid neoplasm</keyword>
  <keyword>fibroblast growth factor receptor inhibitor</keyword>
  <keyword>FGFR1 rearrangement</keyword>
  <keyword>8p11</keyword>
  <keyword>eosinophilia</keyword>
  <keyword>eosinophilic syndrome</keyword>
  <keyword>Lymphoid neoplasm</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

